Matches in Wikidata for { <http://www.wikidata.org/entity/Q66068184> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q66068184 description "assaig clínic" @default.
- Q66068184 description "clinical trial" @default.
- Q66068184 description "clinical trial" @default.
- Q66068184 description "clinical trial" @default.
- Q66068184 description "clinical trial" @default.
- Q66068184 description "ensaio clínico" @default.
- Q66068184 description "ensayo clínico" @default.
- Q66068184 description "ensayu clínicu" @default.
- Q66068184 description "essai clinique" @default.
- Q66068184 description "klinisch onderzoek" @default.
- Q66068184 description "клінічне випробування" @default.
- Q66068184 description "կլինիկական փորձարկում" @default.
- Q66068184 name "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 name "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 type Item @default.
- Q66068184 label "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 label "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 prefLabel "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 prefLabel "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 P1050 Q66068184-BF77C6B1-8AF5-41A0-A655-9BE7FF3687DF @default.
- Q66068184 P1132 Q66068184-5D9B52B1-2168-4715-801E-4EA295478460 @default.
- Q66068184 P1476 Q66068184-492B67B3-76E5-4354-9E47-A196B9287C76 @default.
- Q66068184 P1813 Q66068184-FF2B6EEC-D1F9-4104-AB1F-A772A667B6F6 @default.
- Q66068184 P2899 Q66068184-2A00A9FC-5222-423C-B006-A2DFF7EFB439 @default.
- Q66068184 P3098 Q66068184-5E9763C4-B829-493C-8540-636157250706 @default.
- Q66068184 P31 Q66068184-D323AFC3-8F53-4D13-AD3F-CCADB3B6F6EF @default.
- Q66068184 P4844 Q66068184-F81F1206-9F7C-4E14-9590-1D0B2789039C @default.
- Q66068184 P580 Q66068184-F795A197-F3EE-49A9-8072-277A5CEE73B2 @default.
- Q66068184 P582 Q66068184-B6D800FC-6C64-4418-B13E-DEE5F791EA22 @default.
- Q66068184 P6099 Q66068184-FAA4933B-51AE-47F6-822B-F74E699B87DE @default.
- Q66068184 P767 Q66068184-27EF736B-BB6D-42F2-A4A9-E91BA76F6694 @default.
- Q66068184 P8363 Q66068184-C1F78E6D-28A5-4998-903B-283C61863C1F @default.
- Q66068184 P1050 Q12204 @default.
- Q66068184 P1132 "+0" @default.
- Q66068184 P1476 "Prospective, Randomized, Partially Blinded, Phase 3 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB" @default.
- Q66068184 P1813 "DRAMATIC" @default.
- Q66068184 P2899 "+12" @default.
- Q66068184 P3098 "NCT03828201" @default.
- Q66068184 P31 Q30612 @default.
- Q66068184 P4844 Q1257318 @default.
- Q66068184 P580 "2020-01-01T00:00:00Z" @default.
- Q66068184 P582 "2024-01-01T00:00:00Z" @default.
- Q66068184 P6099 Q42824827 @default.
- Q66068184 P767 Q507154 @default.
- Q66068184 P8363 Q78089383 @default.